(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Rani Therapeutics Holdings's earnings in 2026 is -$30,141,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$25,244,492, with the lowest RANI earnings forecast at -$25,955,408, and the highest RANI earnings forecast at -$24,882,064. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$27,377,241, with the lowest RANI earnings forecast at -$27,321,483, and the highest RANI earnings forecast at -$24,882,064.
In 2028, RANI is forecast to generate $658,308,334 in earnings, with the lowest earnings forecast at -$27,321,483 and the highest earnings forecast at $2,780,936,614.